An integrin αvβ3 antagonistic modified peptide inhibits tumor growth through inhibition of the ERK and AKT signaling pathways

Hu,Lirong; Wang,Jingjing; Wang,Ying; Xu,Hanmei

doi:10.3892/or.2016.4994

An integrin αvβ3 antagonistic modified peptide inhibits tumor growth through inhibition of the ERK and AKT signaling pathways

Authors:
- Lirong Hu
- Jingjing Wang
- Ying Wang
- Hanmei Xu
View Affiliations

Affiliations: The Engineering Research Center of Peptide Drug Discovery and Development, China Pharmaceutical University, Nanjing, Jiangsu 210009, P.R. China
Published online on: August 2, 2016 https://doi.org/10.3892/or.2016.4994
Pages: 1953-1962

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

HM-3, an RGD (Arg-Gly-Asp)-modified antitumor polypeptide designed independently, has been demonstrated for its robust inhibitory effects on tumors. However, the intravenous administration and short half-life in vivo are inconvenient to its clinical application. To solve these issues, PEGylated HM-3 (mPEG-SC20k-HM-3) with prolonged half‑time in vivo and subcutaneous administration was obtained after repeated screening of different types of PEG and numerous efficacy assays. The present study aimed to evaluate the antitumor activity and investigate the mechanism of the modified peptide to interpret the antitumor properties of mPEG-SC20k-HM-3 comprehensively and clearly. The results of the antitumor activity assays in vitro indicated that mPEG-SC20k-HM-3 exhibited a marked inhibitory activity on tumor metastasis and angiogenesis. mPEG-SC20k-HM-3 (73.4 mg/kg, sc) achieved a tumor inhibitory rate of 70.1% in an H460 (human non-small cell lung cancer) xenograft model with scarce cytotoxicity, compared with a rate of 72.2% for Avastin (10.0 mg/kg, iv). The mechanistic study showed that mPEG-SC20k-HM-3 could target integrin αvβ3 to block the downstream ERK and Akt pathways, as the expression levels of VEGF, Akt1, p-Akt1, ERK1/2, p-ERK1/2, MEK1, p-MEK1, integrin αv and β3 were reduced after HUVECs were incubated with mPEG-SC20k-HM-3 for 24 h. In conclusion, the antitumor activity of mPEG-SC20k-HM-3 in vitro and in vivo is promising and the mechanism was clearly reflected in the present study.

View Figures

View References

1	Ryeom S and Folkman J: Role of endogenous angiogenesis inhibitors in Down syndrome. J Craniofac Surg. 20(Suppl 1): S595–S596. 2009. View Article : Google Scholar
2	Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG and Kerbel RS: Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell. 15:232–239. 2009. View Article : Google Scholar : PubMed/NCBI
3	Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, McArthur G, Judson IR, Heinrich MC, Morgan JA, et al: Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: A randomised controlled trial. Lancet. 368:1329–1338. 2006. View Article : Google Scholar : PubMed/NCBI
4	Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA, Ginsberg MS, Kim ST, Baum CM, DePrimo SE, et al: Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin oncol. 24:16–24. 2006. View Article : Google Scholar
5	Xu H, Pan L, Ren Y, Yang Y, Huang X and Liu Z: RGD-modified angiogenesis inhibitor HM-3 dose: Dual function during cancer treatment. Bioconjug Chem. 22:1386–1393. 2011. View Article : Google Scholar : PubMed/NCBI
6	Yuan D, Shen H, Yuan S, Liu X, Xia X, Xie P, Li W, Hu J, Liu Q and Xu H: Pharmacokinetics of HM-3 after intravitreal administration in mice. Curr Eye Res. 39:837–844. 2014. View Article : Google Scholar : PubMed/NCBI
7	Zhou K, Zheng X, Xu HM, Zhang J, Chen Y, Xi T and Feng T: Studies of poly(ethylene glycol) modification of HM-3 polypeptides. Bioconjug Chem. 20:932–936. 2009. View Article : Google Scholar : PubMed/NCBI
8	Zhu B, Xu HM, Zhao L, Huang X and Zhang F: Site-specific modification of anti-angiogenesis peptide HM-3 by polyethylene glycol molecular weight of 20 kDa. J Biochem. 148:341–347. 2010. View Article : Google Scholar : PubMed/NCBI
9	Liu Z, Ren Y, Pan L and Xu HM: In vivo anti-tumor activity of polypeptide HM-3 modified by different polyethylene glycols (PEG). Int J Mol Sci. 12:2650–2663. 2011. View Article : Google Scholar : PubMed/NCBI
10	Desgrosellier JS and Cheresh DA: Integrins in cancer: Biological implications and therapeutic opportunities. Nat Rev Cancer. 10:9–22. 2010. View Article : Google Scholar
11	Silginer M, Burghardt I, Gramatzki D, Bunse L, Leske H, Rushing EJ, Hao N, Platten M, Weller M and Roth P: The aryl hydrocarbon receptor links integrin signaling to the TGF-β pathway. Oncogene. 10:3872015.
12	Yan F, Xu X, Chen Y, Deng Z, Liu H, Xu J, Zhou J, Tan G, Wu J and Zheng H: A lipopeptide-based αvβ₃ integrin-targeted ultrasound contrast agent for molecular imaging of tumor angiogenesis. Ultrasound Med Biol. 41:2765–2773. 2015. View Article : Google Scholar : PubMed/NCBI
13	Huang C, Jacobson K and Schaller MD: MAP kinases and cell migration. J Cell Sci. 117:4619–4628. 2004. View Article : Google Scholar : PubMed/NCBI
14	Dong F, Tian H, Yan S, Li L, Dong X, Wang F, Li J, Li C, Cao Z, Liu X, et al: Dihydroartemisinin inhibits endothelial cell proliferation through the suppression of the ERK signaling pathway. Int J Mol Med. 35:1381–1387. 2015.PubMed/NCBI
15	Huang Y, Yu J, Wan F, Zhang W, Yang H, Wang L, Qi H and Wu C: Panaxatriol saponins attenuated oxygen-glucose deprivation injury in PC12 cells via activation of PI3K/Akt and Nrf2 signaling pathway. Oxid Med Cell Longev. 2014:9780342014. View Article : Google Scholar : PubMed/NCBI
16	Matsumoto K and Ema M: Roles of VEGF-A signalling in development, regeneration, and tumours. J Biochem. 156:1–10. 2014. View Article : Google Scholar : PubMed/NCBI
17	Ferrara N: Pathways mediating VEGF-independent tumor angiogenesis. Cytokine Growth Factor Rev. 21:21–26. 2010. View Article : Google Scholar
18	Cathcart J, Pulkoski-Gross A and Cao J: Targeting matrix metalloproteinases in cancer: Bringing new life to old ideas. Genes Dis. 2:26–34. 2015. View Article : Google Scholar : PubMed/NCBI